Dr. Kansagra on Expanding Role of CAR T-Cell Therapy in Lymphoma and Multiple Myeloma

Video

Ankit Kansagra, MD, discusses the expanding role of CAR T-cell therapy in lymphoma and multiple myeloma.

Ankit Kansagra, MD, assistant professor, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses the expanding role of CAR T-cell therapy in lymphoma and multiple myeloma.

The utility of CAR T-cell therapy is rapidly growing in oncology, explains Kansagra. In October 2017, the FDA approved axicabtagene ciloleucel (axi-cel; Yescarta) for the treatment of adult patients with relapsed/refractory large B-cell lymphoma following ≥2 lines of systemic therapy. Additionally, in May 2018, the FDA approved tisagenlecleucel (Kymriah) for use in the same indication.

Ongoing clinical trials are investigating the efficacy of moving CAR T-cell therapy into earlier lines of treatment in B-cell lymphomas, says Kansagra.

Data from the 2019 ASH Annual Meeting continue to show unprecedented efficacy with CAR T cells in the treatment of patients with relapsed/refractory multiple myeloma.

Collaborating with CAR T-cell therapy experts, as well as increasing the number of institutions that are certified to treat with immune-based therapies may increase patient access to these treatment modalities, concludes Kansagra.

Related Videos
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
© 2024 MJH Life Sciences

All rights reserved.